艾昆纬-加拿大糖尿病和肥胖症的药物治疗-IQVIA关于2019-2023年药物利用数据的独立报告（英）

Medication Treatments for Diabetes and Obesity in CanadaAn independent IQVIA report on drug utilization data, 2019–2023Introduction 3Treatments for diabetes and obesity 4Highlights of national drug use for diabetes and obesity 5Provincial prevalence highlights 6Demographic analysis 7Prescibers by specialty 10Recommendations for health interest groups 10Data sources and methodology 11This report is based on statistics and analysis from the IQVIA Health Insights dashboard, developed in collaboration with the IQVIA Advisory Council for Health Advancement, a group of Quebec experts from various health sectors. It provides an overview of drug treatment trends for diabetes and obesity in community pharmacies in Canada over a five-year period (2019 to 2023), highlighting variations at the demographic level. A key objective of the Council is to make the dashboard accessible to various health stakeholders (governments, public health, researchers) to demonstrate the added value of using anonymized, evidence-based health data. Refer to page 11 for the limitations associated with using IQVIA data.Note to the reader To correctly interpret the data in this report, it is important to consider the following: • Prevalence is calculated from individuals who received at least one prescription for medication to treat diabetes or obesity; • The obesity prevalence calculation considers only individuals who used medication to treat obesity, including those who received a GLP-1 class antidiabetic medication who do not have diabetes; • Individuals with both obesity and diabetes are included in the diabetes prevalence calculation. This report is produced independently by IQVIA Canada as a public service, without industry or government funding. IQVIA complies with all laws regarding the protection of personal health information and IQVIA does not collect or use any prescription drug data that could identify a patient.Table of contents iqvia.com/canada | 3Introduction Diabetes is a chronic disease that occurs when the body does not produce enough insulin or cannot use it properly, leading to high blood glucose levels. The health consequences for people with diabetes are numerous1. It can cause vascular damage in the heart, eyes, kidneys and nerves. The two main types of diabetes are: • Type 1 diabetes: an autoimmune disease requiring lifelong treatment with insulin. It accounts for between 5% and 10% of cases and cannot be prevented; • Type 2 diabetes: accounts for 90% to 95% of cases and is generally associated with lifestyle habits, although genetic predispositions may also play a role. Prediabetes is characterized by a blood glucose level higher than normal, but insufficient to be classified as type 2 diabetes. It represents a major public health issue that can be mitigated by preventive measures and early interventions. Obesity is characterized by excessive accumulation of body fat and represents a significant risk factor for the development of type 2 diabetes, cr